Cortex Pharmaceuticals

https://www.eqs-news.com/de/news/corporate/sernova-kuendigt-forschungskooperation-mit-dem-pharmakonzern-astrazeneca-an-um-neuartige-potenzielle-zelltherapie-anwendungen-zu-untersuchen/1809733

Und im Alzheimer Thread, ?? Alle werden doch nicht hier schon Alzheimer haben?

wer kauft schon quäkendes silber quäksilber da kann man auch nicht schlafen nachts wenn es zu quäken anfängt lieber echtes silber kaufen, das ist ruhig und steigt schneller an wert ein guter rat von magnusfe ...

Prana Announces Completion of Phase IIa Trial of PBT2 in Alzheimer's Disease Patients MELBOURNE, Australia – January 2, 2008 – Prana Biotechnology Limited (NASDAQ: PRAN / ASX: PBT), a biopharmaceutical company focused on the research and development of treatments for neurodegenerative disorders, today announced it has completed its Phase IIa clinical trial of PBT2 in patients with early Alzheimer's disease. All patients have completed their final clinical assessment. The data are being analysed, and results will be delivered in the first quarter of 2008. Geoffrey Kempler, Chairman and CEO of Prana Biotechnology, said, “The completion of the Phase IIa trial for PBT2 represents a significant milestone in the development of Prana's innovative therapeutic platform for Alzheimer's Disease, and other neurodegenerative diseases.” This Phase IIa trial is a double blind, placebo-controlled study exploring the safety and tolerability of PBT2, Prana’s proprietary lead compound. The trial also measured PBT2’s effects on the mechanism and progression of the disease, by investigating biomarkers of Alzheimer's Disease, as well as measures of cognition. About Prana Biotechnology Limited Prana Biotechnology was established to commercialise research into Alzheimer's disease and other major age-related neurodegenerative disorders. The company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including the University of Melbourne, the Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, discovered Prana’s technology. For further information, please visit our web site at www.pranabio.com.